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Abstract
Despite wide margins and high dose irradiation, unresectable malignant glioma (MG) is less responsive to radiation and is
uniformly fatal. We previously found that cytosolic phospholipase A2 (cPLA2) is a molecular target for radiosensitizing
cancer through the vascular endothelium. Autotaxin (ATX) and lysophosphatidic acid (LPA) receptors are downstream from
cPLA2 and highly expressed in MG. Using the ATX and LPA receptor inhibitor, a-bromomethylene phosphonate LPA (BrP-
LPA), we studied ATX and LPA receptors as potential molecular targets for the radiosensitization of tumor vasculature in MG.
Treatment of Human Umbilical Endothelial cells (HUVEC) and mouse brain microvascular cells bEND.3 with 5 mmol/L BrP-
LPA and 3 Gy irradiation showed decreased clonogenic survival, tubule formation, and migration. Exogenous addition of
LPA showed radioprotection that was abrogated in the presence of BrP-LPA. In co-culture experiments using bEND.3 and
mouse GL-261 glioma cells, treatment with BrP-LPA reduced Akt phosphorylation in both irradiated cell lines and decreased
survival and migration of irradiated GL-261 cells. Using siRNA to knock down LPA receptors LPA1, LPA2 or LPA3 in HUVEC,
we demonstrated that knockdown of LPA2 but neither LPA1 nor LPA3 led to increased viability and proliferation. However,
knockdown of LPA1 and LPA3 but not LPA2 resulted in complete abrogation of tubule formation implying that LPA1 and
LPA3 on endothelial cells are likely targets of BrP-LPA radiosensitizing effect. Using heterotopic tumor models of GL-261,
mice treated with BrP-LPA and irradiation showed a tumor growth delay of 6.8 days compared to mice treated with
irradiation alone indicating that inhibition of ATX and LPA receptors may significantly improve malignant glioma response
to radiation therapy. These findings identify ATX and LPA receptors as molecular targets for the development of
radiosensitizers for MG.
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Introduction
Malignant glioma (MG) is characterized by neovascularization
and invasion into surrounding brain parenchyma, which nega-
tively impacts successful resection [1]. Unresectable MG is
uniformly fatal with a median survival time of one year [2].
Therefore, response to chemotherapeutic and radiation approach-
es are essential to control growth and spread. However, disease
progression occurs within the field of irradiation despite increased
dosage. The identification of new molecular targets for drug
development could significantly improve therapeutic outcomes in
MG.
ATX was originally discovered as a tumor motility protein [3]
from melanoma cells and is a type II membrane protein secreted
by cells [4,5]. It is known to contribute to invasive properties in
non-small cell lung cancer [6], renal cell cancer [7] and most
recently glioblastoma multiforme (GBM) [8]. ATX converts
extracellular lysophosphatidylcholine (LPC) to lysophosphatidic
acid (LPA) through its lysophospholipase D activity [9]. It has been
demonstrated that specific G-protein coupled receptors (GPCRs)
mediate the cellular effects of LPA, such as proliferation and
migration in cancer [10]. Three of seven identified LPA-specific
receptors, Edg-2/LPA1, Edg-4/LPA2, and Edg-7/LPA3, belong
to the endothelial cell differentiation gene (EDG) family and share
approximately 60% homology [11,12]. ATX and LPA receptors
are both highly expressed in MG, and invading MG cells show
increased gene expression of ATX compared to cells in the
originating tumor core [8,13]. Octa-decenyl thiophosphate (OTP),
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transfected with LPA2 but not LPA1 and LPA3 [14]. OTP also
protected intestinal crypt cell viability in irradiated wild type but not
in irradiated LPA2 null mice.[14] Recently, VPC-12249, an LPA1
and LPA3 receptor antagonist was reported to attenuate radiation-
induced pneumonitis in mice [15]. LPA receptors on endothelial
cells can contribute to angiogenesis through the increased
expression and production of neovascularizing factors such as
interleukin (IL) -6, IL-8 and vascular endothelial growth factors
(VEGF) [16]. The ability of a tumor to recruit and generate new
vasculature leads to growth and invasion into surrounding tissue.
The protein kinase B (PKB) or Akt pathway has been implicated
in various diseases like cancer, diabetes and autoimmunity [17,18].
Increased activation of Akt have been reported in melanoma,
breast, colon, ovarian, pancreatic and prostrate cancers
[18,19,20,21] and implicated as a leading cause of chemo- and
radio resistance [21,22]. The effectiveness of radiotherapy is often
limited by the response of the tumor microvasculature [23]. We
previously found that ionizing radiation (IR) induces the activation
of cytosolic phospholipase A2 (cPLA2) in tumor endothelium
which leads to the production of LPC and Akt phosphorylation
resulting in radioresistance of endothelial cells [24]. Moreover, the
inhibition of cPLA2 prior to irradiation leads to the disrupted
endothelial cell function and the destruction of tumor blood
vessels, which translates into suppressed tumor growth [25]. Since
LPC is a known substrate for ATX, we hypothesized that ATX
and LPA receptors might be the effectors of cPLA2 -induced
radioresistance in vascular endothelial cells (Fig. S1). Therefore, in
this study, we investigated whether ATX and LPA receptors could
serve as novel molecular targets for the radiosensitization of MG
through enhanced cytotoxic effects in the tumor vasculature by
using a dual ATX and LPA receptor inhibitor, a-bromomethylene
phosphonate LPA(BrP-LPA)[26,27] .
We found that ATX and LPA receptor inhibition enhanced
radiation-induced endothelial cell death, disrupted endothelial cell
biological function, and reduced glioma cell viability and
migration. Most importantly, BrP-LPA treatment prior to
irradiation repressed glioma tumor growth in vivo. These findings
suggest that ATX and LPA receptors represent potential
molecular targets to enhance the efficacy of radiation therapy.
Results
Inhibition of ATX and LPA receptors enhances cell death
in irradiated HUVEC and bEnd.3 vascular endothelial cells
We recently found that cPLA2 inhibition enhanced cell death in
irradiated 3B11 murine vascular endothelial cells [25]. We
hypothesized that LPC produced by radiation-activated cPLA2 is
converted to LPA by ATX and could activate signaling pathways
through its LPA receptors. To determine whether inhibition of
ATX and LPA receptors leads to radiosensitization of brain
microvascular endothelial cells, we used a-bromomethylene
phosphonate LPA (BrP-LPA), an inhibitor of ATX activity and
a pan-antagonist of four LPA receptors [26,27], to assess
clonogenic survival of irradiated HUVEC. Treatment with BrP-
LPA enhanced cell death in irradiated cells at 2, 4, and 6 Gy
(Fig. 1A). At 2 Gy, ATX and LPA receptors inhibition led to a
45% decrease in survival compared to cells treated with vehicle
control (surviving fractions 0.23 versus 0.07, respectively,
p=0.009; Fig. 1A). Similar effects were observed in bEnd.3 cells
(Fig. 1B). The most pronounced effect occurred at 4 Gy, in which
treatment with BrP-LPA enhanced radiation-induced cell death by
70% compared to corresponding control cells (survival fractions
0.51 versus 0.92, respectively, p=0.04; Fig. 1B).
To determine whether the LPA receptors mediate radiation-
induced cellular responses, we treated HUVEC with 10 mM LPA
in serum free medium with or without 5 mM BrP-LPA. HUVEC
treated with exogenous LPA showed increased survival and
radioprotection compared to untreated cells (Fig. 1C and 1D).
Treatment with BrP-LPA abrogated this radioprotective effect
triggered by exogenous LPA suggesting that radiosensitization by
BrP-LPA could be mediated through the ATX and LPA receptors.
ATX and LPA receptors inhibition attenuates tubule formation
in irradiated vascular endothelial cells. To determine if ATX and
LPA receptors inhibition disrupts the ability of endothelial cells to
form capillary-like tubule structures, HUVEC were plated on
Matrigel-coated 96-well plates. Cells were treated with 5 mM BrP-
LPA or H20 as vehicle control for 45 min before irradiation
(3 Gy). Tubule formation was monitored and recorded at 16 h
after irradiation. Treatment with 3 Gy or BrP-LPA alone resulted
in a slight decrease in the ability of cells to form tubule structures
(Fig. 2A and B). However, the combination of ATX and LPA
receptor inhibition with irradiation resulted in a 53% attenuation
of tubule formation compared to corresponding controls (Fig. 2B,
p=0.0006). Similar results were observed in bEnd.3 cells (Fig. 2C)
in which ATX and LPA receptors inhibition produced a 50%
reduction in the number of tubules formed compared to its
corresponding control (p=0.0039).
Inhibition of ATX and LPA receptors attenuates migration
in irradiated endothelial cells
To determine whether inhibition ATX and LPA receptors
results in reduced endothelial cell migration, a scratch assay was
performed by treating HUVEC and bEnd3 cells with 5 mM BrP-
LPA or H20 as vehicle control for 45 min prior to irradiation
(3 Gy). Migrated cells ware counted and normalized relative to
surrounding cell density at 24 h after irradiation. Combined
treatment with BrP-LPA and 3 Gy significantly attenuated
endothelial cell migration compared to radiation alone in both
HUVEC (Fig. 3A, 70% versus 30%) and bEnd3 cells (Fig. 3B,
80% versus 9%). These results indicate that BrP-LPA is able to
attenuate migration in both HUVEC and bEnd3 cells.
Inhibition of ATX and LPA receptors attenuates migration
and enhances cell death in irradiated GL261 glioma cells
Since glioma cells express high levels of ATX and multiple LPA
receptors [8] , we investigated the effects of BrP-LPA on cell
migration and colony formation in GL261 cells. Treatment of
GL261 cells with either 5 mM BrP-LPA or 3 Gy alone resulted in
a minor reduction in cell migration (81% and 98% of control,
respectively; Fig. 4A and 4B). However, combined treatment with
BrP-LPA and irradiation reduced GL261 migration to 65% of
control (Fig. 4B, p=0.018). In clonogenic survival studies,
irradiated GL261 cells treated with 5 mM BrP-LPA showed a
modest but significantly reduced survival at the radiation dose of
2 Gy compared to cells treated with radiation alone (Fig. 4C).
Inhibition of ATX and LPA receptors disrupts pro-survival
signals in irradiated bEnd.3 and GL261 cells grown in co-
culture
We previously found that irradiation induces cPLA2 activation
in endothelial cells, which leads to LPC production and the
subsequent activation of Akt in tumor endothelium [24]. ATX
expressed by glioma cells may contribute to this pro-survival
signaling by converting LPC to LPA, thereby activating LPA
receptors. To investigate whether ATX and LPA receptors
inhibition can disrupt Akt activation, bEnd.3 and GL261 cells
Inhibition of ATX/LPA Receptor
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22182were grown in co-culture and treated with 5 mM BrP-LPA or
vehicle control 45 min prior to 3 Gy irradiation. Treatment with
5 mM BrP-LPA prior to 3 Gy irradiation reduced Akt activation in
bEnd.3 endothelial cells relative to treatment with 3 Gy radiation
alone (0.54 versus 1.09 fold change relative to control, respectively;
Fig. 5). In GL261, Akt phosphorylation was also reduced in cells
treated with 5 mM BrP-LPA prior to 3 Gy irradiation compared to
treatment with either drug or irradiation alone (0.59 versus 1.01
versus 0.94 fold change relative to control, respectively; Fig. 5).
Knockdown of LPA1 and LPA3 receptors leads to decreased
tubule formation in HUVEC. To determine the role of LPA
receptors in clonogenic survival, proliferation and tubule forma-
tion of irradiated vascular endothelial cells, we used siRNA to
knock down LPA1, LPA2 or LPA3 in HUVEC. Knockdown of
either LPA1 or LPA3 had no effect on cell survival in irradiated
HUVEC compared to the nonsilencing control (Fig. 6A and 6B).
In contrast, knockdown of LPA2 showed increased survival of
irradiated HUVEC in both the clonogenic and proliferation assays
(Fig. 6A and 6B). In tubulogenesis assays, compared to nonsilen-
cing control, knockdown of LPA1or LPA3 demonstrated signifi-
cant decrease in tubule formation (Fig. 6C and 6D) whereas
knockdown of LPA2 showed increased tubule formation (Fig. 6C
and 6D). Upon treatment with 3 Gy, tubules were undetectable in
HUVEC with knocked down LPA1or LPA3; while knockdown of
LPA2 did not show any change in tubule formation compared to
nonsilencing control. These results indicate that LPA2 is involved
in radiation-induced cell death and decreased tubule formation in
endothelial cells, and likely, does not take part in radiosensitizing
effects of BrP-LPA. On the contrary, while LPA1 and LPA3 do
not play noticeable role in radiation-dependent viability of
endothelial cells, they are critical for tubule formation.
Inhibition of ATX and LPA receptors represses tumor
growth in irradiated GL261 mouse model
To determine the efficacy of ATX and LPA receptor inhibition
in vivo, a heterotopic mouse brain tumor model was used. GL261
Figure 1. Inhibition of ATX and LPA receptors enhances cell death in irradiated vascular endothelial cells. (A) HUVEC or (B) bEnd.3 cells
were treated with vehicle control (&)o r5mM BrP-LPA (m) for 45 min prior to irradiation. (C) HUVEC were treated with 0.1% fatty acid free BSA (N),
10 mM LPA (#)o r1 0mM LPA plus 5 mM BrP-LPA (&) in serum free medium for 45 min prior to irradiation. The cells were then irradiated with 0, 2, 4
and 6 Gy and plated for clonogenic survival assay. After 2–3 wks, cells were stained with 1% methylene blue and colonies consisting of .50 cells
were counted by microscopy. Surviving colonies were normalized for plating efficiency. Shown are average survival fractions and SEM from three
experiments; * p,0.05. (D) Equal numbers of HUVEC were plated in 96 well plates and treated with carrier control 3% fatty acid free BSA, 10 mM LPA
or 10 mM LPA with 5 mM BrP-LPA in serum free medium for 45 min prior to irradiation. After 96 h, the cell viability was determined using a
colorimetric cell proliferation assay (Promega). Shown is the average absorbance at 490 nm with SEM from three experiments; * p,0.05.
doi:10.1371/journal.pone.0022182.g001
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5) were injected s.c. into the right hind limbs of nude
mice. Tumor-bearing mice were then treated with vehicle alone,
irradiation alone (5 fractions of 3 Gy), 3 mg/kg BrP-LPA alone, or
3 mg/kg BrP-LPA for 45 min followed by irradiation (5 fractions
of 3 Gy). Treatment with either BrP-LPA or irradiation alone
delayed tumor growth relative to control (1.2 days and 12.0 days,
respectively; Fig. 7). The most pronounced tumor growth delay,
however, was observed in mice receiving a combination of BrP-
LPA and irradiation. In this treatment group, the tumor growth
delay was 6.8 days relative to treatment with irradiation alone
(p=0.03). This difference remained statistically significant
(p=0.0005) after using Holm’s correction for multiple compari-
sons, and a 2
2 factorial design study of tumor growth delay
revealed an additive interaction between BrP-LPA and irradiation.
Discussion
Despite the use of multiple treatment modalities including
chemotherapy and radiation therapy, unresectable MG is
characterized by poor cure rates and high frequencies of
Figure 2. Inhibition of ATX and LPA receptors attenuates tubule formation in irradiated vascular endothelial cells. (A, B) HUVEC or (C)
bEnd.3 cells were plated on matrigel-coated 96 well plates and treated with vehicle control or 5 mM BrP-LPA for 45 min prior to irradiation with 3 Gy.
(A) Shown are the representative photomicrographs of tubule formation taken 16 h after irradiation. (B) Tubule formation was quantified as number
of tubules per high power field (HPF). Shown are bar graphs of mean number of tubules per HPF relative to control and SEM from three experiments;
*p ,0.05.
doi:10.1371/journal.pone.0022182.g002
Inhibition of ATX/LPA Receptor
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22182recurrence. A significant contributor to poor treatment outcomes
is the highly motile phenotype exhibited by MG that allows
invasion into surrounding parenchyma and makes it incurable by
localized therapies [28]. Tumor growth and spread require a
vascular framework that depends on endothelial cell migration
and angiogenesis [29]. In addition, the endothelium is important
because it has been shown that tumor vascular responses to
ionizing radiation largely affect tumor radiosensitivity [23,24].
While it is possible that some cytotoxicity could occur within the
normal vasculature, it would be limited since radiation is
primarily cytotoxic to rapidly dividing cells. Tumor endothelial
cells proliferate 20 to 2000 times faster than normal tissue
endothelium[30].
We previously found that cPLA2 activation in endothelial cells
occurs within minutes of exposure to IR. Inhibition of cPLA2 leads
to decreased survival and angiogenesis in irradiated endothelial
cells, as well as enhanced lung cancer radiosensitivity in vivo [25].
The significance of this pathway may be amplified in MG, where
radiosensitizing the tumor vasculature may not only improve
tumor response to radiotherapy, but may also diminish angiogen-
esis-dependent tumor growth and spread. In the present study, we
found that ATX and LPA receptors, molecular targets down-
stream of cPLA2, can be inhibited in MG to enhance radiation-
induced destruction of endothelial cell functions and improve
tumor response to irradiation. Using a clonogenic survival assay,
we first found that inhibition of ATX and LPA receptors prior to
irradiation enhances endothelial cell death. In HUVEC, reduced
clonogenicity was observed after treatment with BrP-LPA and
radiation compared to treatment with radiation alone. Similar
effects were observed in brain microvascular endothelial cells
(Fig. 1). These results support previously observed enhanced
cytotoxicity after inhibition of the upstream molecular target,
cPLA2, in HUVEC and 3B11 tumor vascular endothelial cells
[25].
LPA is present in the serum in the concentrations of 5–
10 mmol/L [31]. Exogenous addition of LPA to serum free
medium protected HUVEC from radiation damage (Fig. 1C and
1D) confirming a critical role for LPA in radiosensitivity of
Figure 3. Inhibition of ATX and LPA receptors reduces irradiated vascular endothelial cell migration. (A) bEnd.3 or (B) HUVEC were
plated on 60 mm plates and allowed to grow to 70% confluency. The semi-confluent cell layer was scraped using a sterile pipette tip to create a
scratch devoid of cells. The remaining cells were treated with vehicle control or 5 mM BrP-LPA for 45 min prior to irradiation with 3 Gy. Migration was
observed at 36 h. Cells were fixed with ethanol and stained with 1% methylene blue. Migrated cells were counted and normalized to surrounding cell
density per HPF. Shown are representative photomicrographs and bar graphs representing the mean percentages of migrating cells relative to
corresponding controls with SEM from three experiments, * p,0.05.
doi:10.1371/journal.pone.0022182.g003
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abrogated LPA-induced radioprotection (Fig. 1C) suggesting
involvement of LPA receptors in activation of pro-survival
radioprotective signaling pathway in vascular endothelial cells.
Interestingly, the effects of BrP-LPA were not limited to
endothelial cells, and enhanced cell death was also observed in
irradiated GL261 glioma cells (Fig. 4). One potential mechanism
may involve diminished activation of the pro-survival kinase Akt.
LPA, which is produced by ATX and acts through LPA receptors,
has been shown to transiently phosphorylate Akt in C6 glioma
cells [32]. Moreover, cPLA2 inhibition reduces phospho-Akt in
irradiated endothelial cells [25]. Akt inhibitor IV has been shown
to inhibit colony formation in malignant glioma cell line SF763. It
has been shown that Akt activation is linked to glioma radio-
resistance and down regulation of Akt signaling induces apoptosis
and reduced motility of these cells [33]. Consistent with these
findings, we demonstrated that ATX and LPA receptors inhibition
reduced Akt phosphorylation in both irradiated brain endothelial
and glioma cells (Fig. 5).
We also found that ATX and LPA receptors inhibition
enhances the efficacy of radiation to disrupt endothelial cell
tubule formation and migration. In HUVEC and bEnd.3
endothelial cells, treatment with 5 mM BrP-LPA prior to 3 Gy
significantly reduced endothelial cell tubule formation and
migration compared to treatment with 5 mM BrP-LPA or
irradiation alone (Fig. 2 and Fig. 3). Angiogenesis is a complex
process that requires both endothelial cell migration and tubule
formation [29]. The growth and spread of cancer requires an
underlying vascular framework to provide nutrients for expanding
cells [34,35]. MG is particularly prone to invade normal brain
which complicates the ability of current treatment regimens to
prevent recurrence [28]. Therefore, the disruption of endothelial
cell angiogenic functions like tubule formation and migration may
be particularly important in MG. In the present study, the anti-
migratory effects of BrP-LPA were not limited to endothelial cells,
and ATX and LPA receptors inhibition also reduced the ability of
irradiated GL261 glioma cells to migrate in the scratch assay
(Fig. 4). Although ATX and LPA receptors have never been
Figure 4. Inhibition of ATX and LPA receptors attenuates
migration and enhances cell death in irradiated GL261 cells. (A,
B) Mouse glioma GL261 cells were plated on 60 mm plates and allowed
to grow to 70% confluency. Plates were scraped with a pipette tip to
create a scratch devoid of cells and treated with vehicle control or 5 mM
BrP-LPA for 45 min before irradiation with 3 Gy. After 24 h, cells were
fixed and stained with methylene blue. Migrated cells were counted
and normalized to surrounding cell density per HPF. Shown are
representative photomicrographs (A) and a bar graph (B) representing
the mean percentages of migrating cells relative to corresponding
controls with SEM from three experiments; * p,0.05. (C) For clonogenic
survival assay, GL261 cells were plated and allowed to attach. After 6 h,
cells were treated vehicle control or with 5 mM BrP-LPA for 45 min and
irradiated with 0, 2, 4, and 6 Gy. After 10 days, surviving colonies (.50
cells) were counted and normalized for plating efficiency. Shown is the
clonogenic survival curve and mean surviving fractions and SEM from
three experiments; * p,0.05.
doi:10.1371/journal.pone.0022182.g004
Figure 5. Inhibition of ATX and LPA receptors reduces Akt
phosphorylation in irradiated glioma and endothelial cells
grown in co-culture. bEnd.3 and GL261 cells were grown in co-
culture for 24 h. Cells were treated with vehicle or 5 mM BrP-LPA control
for 45 min before treatment with 3 Gy. Cells were lysed at 5 min after
irradiation. Shown are immunoblot analyses using specific antibodies to
phospho-Akt
Thr308/Ser473, total Akt, and actin. Numbers represent the
ratios of phospho-Akt to total Akt protein normalized to actin (fold
change relative to control).
doi:10.1371/journal.pone.0022182.g005
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suggested important roles for these molecular targets in tubule
formation and cell motility. In ovarian cancer cell lines, LPA
contributes to angiogenesis by stimulating the neovascularizing
factors IL-6, IL-8, and vascular endothelial growth factor (VEGF)
expression [16], and ATX modulates cell responsiveness to VEGF
[36]. Diminished mRNA levels of LPA receptors are associated
with abolished HUVEC migration in response to upstream
signaling lipids LPC and LPA [36], and ATX has been shown
to induce LPA receptor-dependent glioma cell motility [8].
Interestingly, LPA induces the phosphorylation of the regulatory
light chain of myosin II in glioma cells [37], which may play a role
in the disrupted motility we observed in irradiated GL261 cells
(Fig. 5).
The ATX and LPA receptors inhibitor BrP-LPA we used has
also been studied in A549 non-small cell lung cancer [27] and
MDA-MB-231 breast cancer [38] cells at doses ranging from 10 to
40 mM, but its effects have never been studied in endothelial cells
or in conjunction with radiation. BrP-LPA is both an ATX and
pan LPA receptor antagonist [27], making it difficult to study the
differential effects of each molecular target individually. We found
potential therapeutic benefit of inhibiting both these targets
downstream from cPLA2, thus indicating that the development
of more potent, specific inhibitors of ATX and LPA receptors is
needed. A specific ATX substrate LPC is abundantly present in
plasma, ranging 100–200 mM [39]. In the presence of such high
concentration of a substrate, BrP-LPA is less likely to inhibit ATX
activity. It is more likely that BrP-LPA is acting at the level of the
LPA receptors. LPA1 and LPA3 have been reported to be
involved in inflammation leading to radiation pneumonitis [15].
LPA2 has been reported to protect against radiation induced
intestinal injury [14]. In our studies, we observed that LPA2
knockdown produced increased viability and proliferation in
irradiated HUVEC compared to nonsilencing controls, while
knockdown of LPA1 or LPA3 did not show any effect (Fig. 6A,
and B). These results suggest that LPA2, but neither LPA1 or
LPA3, is an important factor in transduction of radiation-induced
cell death in vascular endothelial cells. Further, we observed that
knockdown of either LPA1 or LPA3 led to no tubule formation in
HUVEC (Fig. 6 C and D), demonstrating that LPA1 and LPA3
are critical for endothelial cell functions. These results also imply
that LPA1 and LPA3, but not LPA2, involved in radiosensitizing
effects of BrP-LPA. This observation is supported by the results
from another group stating that LPA1 and LPA3 are involved in
Figure 6. Effects of knockdown of LPA1, LPA2 and LPA3 on survival and tubule formation of irradiated HUVEC. HUVEC were
transiently transfected with the non-silencing (N) or LPA1- (&), LPA2- (m) or LPA3- (¤) specific siRNA. (A) The knocked down cells were then irradiated
with 0, 2, 4 and 6 Gy and plated for clonogenic survival assay. After 2–3 wks, cells were stained with 1% methylene blue and colonies consisting of
.50 cells were counted by microscopy. Surviving colonies were normalized for plating efficiency. Shown are average survival fractions and SE from
three experiments; * p,0.05. (B) Equal numbers of knocked down cells were plated in 96 well plates and irradiated with 3 Gy. After 96 h, the cell
viability was determined using a colorimetric cell proliferation assay (Promega). Shown is the average absorbance at 490 nm with SEM from three
experiments; * p,0.05. (C, D) The knocked down cells were plated on matrigel-coated 96 well plates and treated with 3 Gy. (C) Shown are the
representative photomicrographs of tubule formation taken 16 h after treatment. (D) Tubule formation was quantified as number of tubules per HPF.
Shown are bar graphs of mean tubules per HPF relative to control and SEM from three experiments; * p,0.05.
doi:10.1371/journal.pone.0022182.g006
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radiosensitization [15]. Therefore, we conclude that LPA1 and
LPA3 on vascular endothelial cells are molecular targets for
radiosensitization and tumor control as endothelium plays a vital
role in tumor growth and invasion, Based on the published
literature, in addition to inhibiting LPA1 and LPA3 on endothelial
cells, BrP-LPA could also function by inhibiting ATX and LPA
receptors on cancer cells (Fig. S1). This possible mode of BrP-LPA
action requires further investigation.
Summarizing the present study, we characterize the important
role of ATX and LPA receptors in the vascular response to
irradiation. We found that the inhibition of these targets enhances
the ability of radiation to induce endothelial cell death, disrupt
endothelial cell tubule formation, and attenuate endothelial cell
migration. Most importantly, inhibition of ATX and LPA
receptors along with radiation therapy in a heterotopic mouse
model repressed overall GL261 tumor growth (Fig. 7). Moreover,
radiosensitization of the tumor vasculature may contribute to
tumor growth delay. These findings suggest that pre-treatment
with drugs that inhibit ATX and LPA receptors may significantly
improve malignant glioma response to radiation therapy. Clinical
trials with such drugs will be required before any clinical benefit
can be determined.
Materials and Methods
Cell cultures and treatment
Mouse brain microvascular (bEnd.3) cells were obtained from
ATCC and maintained in DMEM with 10% FBS and 1%
penicillin/streptomycin (Life Technologies, Gaithersburg, MD).
Human umbilical vein endothelial cells (HUVEC) were obtained
from and quality tested by Lonza and maintained in endothelial cell
growth medium (Lonza, Switzerland). GL261 cells were obtained
from Dr. Yancie Gillespie (University of Alabama-Birmingham,
Birmingham, AL) and maintained in DMEM-F12 with 10% FBS
and 1% penicillin/streptomycin. GL261 cells were MAP tested by
Department of Comparative Medicine at Washington University
and were negative for mycoplasma. All cells were grown in a 5%
CO2 incubator at 37uC. To inhibit ATX and LPA receptors, we
used a-bromomethylene phosphonate LPA (BrP-LPA) which was
purchased from Echelon (Salt Lake City, UT). For the radiation of
cells, a PANTAK pmc1000 x-ray machine with a 0.1 Cu
+ 2.5 AL
filter was used at a dose rate of 88.7 cGy/min.
Clonogenic survival
Cells were plated in triplicate onto 6 cm plates and allowed to
attach for 6 h. Cells were then treated with 5 mM BrP-LPA or H20
Figure 7. Inhibition of ATX and LPA receptors represses tumor growth in irradiated GL261 mouse model. GL261 cells were injected into
the hind limbs of nude mice. Tumors were irradiated with 3 Gy for 5 consecutive days for a total of 15 Gy. Mice were treated with 3 mg/kg BrP-LPA or
vehicle control for 45 min prior to irradiation on days 1, 3, and 5. (A) Shown are mean tumor volumes with SEM from each treatment group of 5 mice.
(B) Tumor growth delay was calculated as the number of days for tumors to reach a 6-fold volume increase compared to control. Shown is a bar
graph representing the mean tumor growth delay with SEM from each treatment group of 5 mice; * p,0.05.
doi:10.1371/journal.pone.0022182.g007
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6 Gy. Cells were incubated at 37uCi n5 %C O 2 for 10–20 days
depending on cell type. Cells were fixed with 70% ethanol and
stained with 1% methylene blue and colonies comprised of more
than 50 cells were counted using microscopy. Average survival
fraction of the treatment was calculated as (number of colonies/
number of cells plated)/(number of colonies of corresponding
control/number of cells plated) with standard error.
Colorimetric cell proliferation assay
Cell proliferation was determined using cell titer 96 Aqueous
Non-Radioactive Cell Proliferation Assay reagent (Promega). The
assay was done following the manufacturers protocol. Briefly equal
numbers of HUVEC cells of various treatments were plated into
different wells of a 96-well plate. Cell viability was determined
colorimetrically by measuring absorbance at 490 nm after
96 hours after treatment. Experiments were done in triplicate
and average fold changes relative to control and standard errors
were calculated.
Matrigel-based tubule formation assay
96-well plates were coated with 75 mL per well of Matrigel
(BD Biosciences, San Jose, CA) and incubated overnight at
37uC. bEnd.3 cells (1.5610
4 ) or HUVEC cells (10
4)w e r ep l a t e d
over the solidified matrigel and allowed to attach at 37uCf o r
45 min prior to treatment. Cells were treated with 5 mMB r P -
LPA or H20 as vehicle control for 45 min and irradiated with
3 Gy. Capillary-like tubule formation was monitored in control
wells (16–24 h) using a microscope, photomicrographs of the
cells were recorded, and the number of tubules per 4 randomly
selected high power fields (HPF) was counted. Tubule formation
was quantified as the average number of tubules per HPF
normalized to control. The experiment was done in triplicate
and the mean and standard error were calculated for each
treatment group.
Cell migration assay
BEnd.3, HUVEC, or GL261 cells were plated in triplicate onto
6 cm plates and allowed to grow to 70% confluency. The semi-
confluent cell layer was scratched with a sterile pipette tip to create
a scratch devoid of cells and plates were washed twice with PBS to
remove nonadherent cells and debris. Cells were treated with
5 mM BrP-LPA or H20 for 45 min prior to irradiation with 3 Gy,
and then incubated at 37uCi n5 %C O 2. Control plates were
monitored for cell migration (20–24 h). Cells were fixed with 70%
ethanol and stained with 1% methylene blue. To quantify
migration, cells in 3 randomly selected high power fields (HPF’s)
in the scratched area were counted and normalized for
surrounding cell density. Mean and standard error for each
treatment group were calculated.
Transfection of siRNA
The silencer select pre-designed siRNAs targeting LPA1, LPA2,
and LPA3 and nontarget control siRNA were obtained from
Applied Biosystems/Ambion. siRNAs were delivered into cells
using HiPerFect transfecting reagent according to the manufac-
turer’s protocol (QIAGEN Valencia, CA). siRNA induced gene
knockdown was confirmed by immunoblotting for LPA1, LPA2
and LPA3 48 hours after siRNA deliveryLPA treatment LPA was
purchased from Avanti Polar Lipids Inc. LPA was applied to the
cells complexed with 3% fatty acid free bovine serum albumin
(Sigma chemical Co., St Louis, MO). Briefly, HUVECs cells were
serum-starved with endothelial cell growth medium (Lonza) for1 h
and treated with 10 mM LPA prior to irradiating or treating with
BrP-LPA.
Co-culture Western immunoblot analysis bEnd.3 cells
(2.5610
5) were plated in 6 well plates and after 24 h, GL261
(5610
5) cells were plated onto transwell inserts (Corning Inc.,
Corning, NY). After co-culture for 24 h, cells were treated with
5 mM BrP-LPA or H20 for 45 min prior to treatment with 3 Gy.
After 5 min, bEnd.3 and GL261 cells were harvested for protein
extraction using M-PER kit (Pierce, Rockford, IL). Protein
concentrations were estimated using BCA Reagent (Pierce,
Rockford, IL) and 30 mg of each sample was subjected to
Western immunoblot analysis using specific antibodies to
phospho-Akt and total Akt (both from Cell Signaling Technol-
ogies, Danvers, MA). Antibody to actin (sigma) was used to
evaluate protein loading in each lane. Immunoblots were
developed using the Western Lightning Chemiluminescence Plus
detection system (PerkinElmer, Wellesley, MA) according to the
manufacturer’s protocol. Band densities were quantitated using
BioRad Quantity One software.
Mice, treatment and tumor growth delay
All animal procedures used in this study were approved by the
Department of Comparative Medicine (DCM) at Washington
University (Animal Studies Committee approval number
20090226), and the housing and handling of animals followed
DCM guidelines. GL261 cells (1610
5) were injected into the right
hind limb of nude mice. Once tumors were palpable (The
average tumor size was 96.82 mm
3), mice were stratified into four
treatment groups of 5 mice representing similar distributions of
tumor sizes. Tumors from two groups of mice were irradiated
with 3 Gy fractions daily for 5 consecutive days for a total of
15 Gy. These mice received 3 mg/kg BrP-LPA or H20a sv e h i c l e
control i.p. 45 min prior to irradiation on the first, third, and fifth
day of treatment. The two groups of non-irradiated mice received
3 mg/kg BrP-LPA or H20 alone at the same times as the
irradiated mice. Tumor volumes were measured using external
caliper. Tumor volumes for each animal were normalized to the
initial tumor volume at the start of treatment, and the mean
tumor fold increase and standard error were calculated for each
treatment group.
Statistical analyses
The mean and SE of each treatment group were calculated for
all experiments. The number of samples is indicated in the
description of each figure. Statistical analysis was done using a
student’s t-test to compare two means with p,0.05 representing
statistical significance. For the in vivo tumor growth delay study, a
2
2 factorial design was used. The t-test using Holm’s correction for
multiple comparisons was used to test significance between group
means. The standard deviation used for the multiple comparisons
was obtained by pooling the standard deviations of the test groups.
The factorial design was also analyzed in terms of variable effects
in order to determine if BrP-LPA/IR interaction was synergistic or
additive.
Supporting Information
Figure S1 Schematic representation of proposed auto-
taxin (Lyso PLD) signaling in cancer. Ionizing radiation
induces production of lipid second messenger LPC. LPC is
converted to LPA by ATX which is highly expressed in cancer
cells. LPA in turn activates LPA receptor signaling leading to
angiogenesis, cancer cell migration and vascular permeability.
(TIF)
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